标准化变应原皮下免疫治疗变应性鼻炎合并咳嗽变异性哮喘患儿的效果观察
Effect of subcutaneous immunotherapy with standardized allergens on children with allergic rhinitis complicated with cough vari-ant asthma
张红颖 1邵磊 1唐燕萍1
作者信息
摘要
目的 观察标准化变应原皮下免疫治疗(SCIT)对变应性鼻炎合并咳嗽变异性哮喘(CVA)患儿的治疗效果.方法 回顾性选取2021年9月至2022年12月淳安县第一人民医院收治的变应性鼻炎合并CVA患儿76例.其中38例患儿采用标准化变应原SCIT,为观察组;另38例患儿采用常规单纯药物对症治疗,为对照组.观察并比较两组患儿疗效及不良反应(包括口舌瘙痒、胃肠道不适、荨麻疹、眼结膜出血、喘憋等)发生情况.结果 观察组患儿治疗总有效率高于对照组,差异有统计学意义(94.74％比76.32％,P＜0.05).观察组患儿不良反应发生率与对照组患儿比较差异无统计学意义(15.79％比18.42％,P＞0.05).结论 标准化变应原SCIT能够显著改善变应性鼻炎合并CVA患儿的鼻炎及哮喘症状,且具有一定的安全性.
Abstract
Objective To observe the efficacy of subcutaneous immunotherapy(SCIT)with standardized allergen in the treatment of children with allergic rhinitis combined with cough variant asthma(CVA).Methods Seventy-six children with allergic rhinitis complicated with CVA admitted to the First People's Hospital of Chun'an County from September 2021 to December 2022 were retrospectively selected.Among them,38 patients were treated with standardized allergen SCIT as the observation group,while the other 38 patients were treated with conventional symptomatic medication alone as the control group.The efficacy and adverse reactions(including oral pruritus,gastrointestinal discomfort,urticaria,eye conjunctival hemorrhage,dyspnea,etc.)were observed and compared between the two groups.Results The total effective rate in the observation group was higher than that in the control group,and the difference was statistically significant(94.74％vs.76.32％,P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation and control groups(15.79％vs.18.42％,P＞0.05).Conclusion Standardized allergen SCIT can significantly improve rhinitis and asthma symptoms in children with allergic rhinitis complicated with CVA,which shows certain safety.
关键词
标准化变应原皮下免疫治疗/变应性鼻炎/咳嗽变异性哮喘/炎症因子Key words
Subcutaneous immunotherapy with standardized allergen/Allergic rhinitis/Cough variant asthma/Inflamma-tory factor引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据